Stockreport

Nurix Therapeutics: Why This Company Could Double In Value? [Seeking Alpha]

Nurix Therapeutics, Inc. - Common stock  (NRIX) 
PDF Phase 1 data showed an 83% response rate at 600mg and 22.1 months of progression-free survival, enabling direct advancement to phase 3 trials. NRIX holds $680M in cas [Read more]